Furthermore, while mutations in driver oncogenes such as K-RAS in lung cancer are commonly associated with poor outcome [31,32,33], many studies failed to detect a significant association between these clinical data and prognosis [34,35,36]. This evidence concerns the gene KRAS and lung cancer.